Financial stability is rapidly eroding, evidenced by a current ratio of 0.61 and the emergence of $138,000 in debt as of 2024Q4, marking a departure from its previously debt-free status.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 |
|---|
| Total Current Assets | 1.34M | 2.05M | 3.81M | 6.24M | 6.12M | 6.83M | 8.2M | 6.21M | 2.75M | 4.26M | 3.12M | 5.09M | 3.79M | 1.58M | 1.22M | 557K | 3.39M | 13.9M | 26.1M | 13.79M | 23.77M | 22.97M |
| Cash & Short-Term Investments | 1.14M | 2.01M | 3.72M | 6.13M | 6.04M | 6.73M | 8.12M | 6.09M | 2.43M | 4.07M | 2.16M | 4.17M | 3.31M | 1.5M | 1.07M | 412K | 2.96M | 12.98M | 25.35M | 13.36M | 22.92M | 22.26M |
| Cash Only | 371K | 1.4M | 2.09M | 2.97M | 3.63M | 4.46M | 3.25M | 3.29M | 2.02M | 3.82M | 2.16M | 2.89M | 1.7M | 123K | 1.07M | 412K | 2.92M | 2.38M | 4.4M | 13.36M | 12.79M | 4.18M |
| Short-Term Investments | 772K | 605K | 1.63M | 3.16M | 2.41M | 2.27M | 4.87M | 2.81M | 414K | 251K | 0 | 1.28M | 1.62M | 1.37M | 0 | 0 | 40K | 10.6M | 20.95M | 0 | 10.14M | 18.08M |
| Accounts Receivable | 99K | 29K | 71K | 94K | 0 | 0 | 0 | 0 | 12K | 0 | 13K | 126K | 126K | 68K | 110K | 105K | 354K | 352K | 444K | 431K | 849K | 706K |
| Days Sales Outstanding | 80.12 | - | - | - | - | - | - | - | - | - | - | 19.41 | 49.03 | - | - | - | 21.75 | 141.65 | 356.96 | 49.21 | 89.72 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 85K | 130K | 0 | 892K | 302K | 229K | 0 | 0 | 0 | 0 | 553K | 287K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | 1000K | 148.76 | 219.96 | - | - | - | - | 1.83K | 1.94K | - | - | - |
| Other Current Assets | 47K | -18K | -57K | -78K | 13K | 20K | 0 | 0 | 179K | 137K | 563K | 390K | 78K | 21K | 0 | 40K | 71K | 19K | 47K | 0 | 0 | 0 |
| Total Non-Current Assets | 7.21M | 380K | 380K | 381K | 382K | 382K | 380K | 380K | 263K | 1.06M | 2.52M | 2.93M | 7.29M | 2.49M | 2.58M | 158K | 41K | 226K | 804K | 1.36M | 1.85M | 1.89M |
| Property, Plant & Equipment | 187K | 0 | 0 | 1K | 2K | 2K | 0 | 0 | 10K | 11K | 24K | 61K | 72K | 32K | 35K | 23K | 41K | 106K | 490K | 762K | 908K | 1.05M |
| Fixed Asset Turnover | 2.41x | - | - | - | - | - | - | - | - | - | - | 38.84x | 13.03x | - | - | - | 144.88x | 8.56x | 0.93x | 4.20x | 3.80x | - |
| Goodwill | 3.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.82M | 380K | 380K | 380K | 380K | 380K | 380K | 380K | 253K | 1.04M | 2.5M | 2.87M | 4.89M | 2.46M | 2.54M | 0 | 0 | 11K | 25K | 39K | 0 | 0 |
| Long-Term Investments | 14K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.34M | 0 | 0 | 135K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 109K | 270K | 559K | 943K | 832K |
| Total Assets | 8.55M | 2.43M | 4.19M | 6.62M | 6.5M | 7.21M | 8.57M | 6.59M | 3.02M | 5.32M | 5.64M | 8.02M | 11.09M | 4.07M | 3.8M | 715K | 3.43M | 14.13M | 26.9M | 15.15M | 25.62M | 24.85M |
| Asset Turnover | 0.05x | - | - | - | - | - | - | - | - | - | - | 0.30x | 0.08x | - | - | - | 1.73x | 0.06x | 0.02x | 0.21x | 0.13x | - |
| Asset Growth % | 252.43% | -42.04% | -36.75% | 1.77% | -9.83% | -15.9% | 30.2% | 118.3% | -43.32% | -5.69% | -29.58% | -27.7% | 172.18% | 7.27% | 431.05% | -79.15% | -75.72% | -47.48% | 77.55% | -40.87% | 3.1% | - |
| Total Current Liabilities | 2.21M | 206K | 187K | 231K | 254K | 232K | 253K | 300K | 330K | 436K | 965K | 1.22M | 1.65M | 629K | 963K | 708K | 2M | 5.37M | 3.4M | 2.41M | 3.53M | 3M |
| Accounts Payable | 196K | 1K | 2K | 2K | 2K | 1K | 253K | 4K | 17K | 118K | 217K | 615K | 596K | 629K | 963K | 708K | 416K | 2.14M | 941K | 2.01M | 3.13M | 3M |
| Days Payables Outstanding | 159.69 | - | 730 | 730 | 730 | - | - | - | - | - | 1000K | 302.94 | 572.47 | - | - | - | - | 7.11K | 6.36K | 261.91 | 346.53 | - |
| Short-Term Debt | 138K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35K | 0 | 0 | 0 | 0 | 0 | 0 | 399K | 0 | 0 | 0 |
| Other Current Liabilities | 1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 450K | 166K | 619K | 0 | -963K | 0 | 530K | 1.56M | 143K | 399K | 399K | 0 |
| Current Ratio | 0.61x | 9.93x | 20.35x | 27.00x | 24.10x | 29.44x | 32.39x | 20.69x | 8.35x | 9.78x | 3.24x | 4.17x | 2.30x | 2.52x | 1.27x | 0.79x | 1.69x | 2.59x | 7.67x | 5.73x | 6.73x | 7.65x |
| Quick Ratio | 0.61x | 9.93x | 20.35x | 27.00x | 24.10x | 29.44x | 32.39x | 20.40x | 7.95x | 9.78x | 2.31x | 3.93x | 2.16x | 2.52x | 1.27x | 0.79x | 1.69x | 2.49x | 7.59x | 5.73x | 6.73x | 7.65x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | -134.76 | -303.48 | - | - | - | - | -5.14K | -4.06K | - | - | - |
| Total Non-Current Liabilities | 908K | 0 | 0 | 1.05M | 2.64M | 465K | 0 | 2.67M | 0 | 0 | 0 | 11K | 13K | 0 | 0 | 0 | 0 | 194K | 738K | 1.49M | 2.49M | 1.24M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 219K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 689K | 0 | 0 | 1.05M | 2.64M | 465K | 0 | 2.67M | 0 | 0 | 0 | 11K | 13K | 0 | 0 | 0 | 0 | 194K | 738K | 1.49M | 2.49M | 1.24M |
| Total Liabilities | 3.12M | 206K | 187K | 1.28M | 254K | 232K | 253K | 2.97M | 330K | 436K | 965K | 1.23M | 1.66M | 629K | 963K | 708K | 2M | 5.56M | 4.14M | 3.9M | 6.02M | 4.25M |
| Total Debt | 138K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -233K | -1.4M | -2.09M | -2.97M | -3.63M | -4.46M | -3.25M | -3.29M | -2.02M | -3.82M | -2.16M | -2.89M | -1.7M | -123K | -1.07M | -412K | -2.92M | -2.38M | -4.4M | -13.36M | -12.79M | -4.18M |
| Debt / Equity | 0.03x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.16x | - | - | - | - | - | -0.28x |
| Interest Coverage | -13.13x | -191.30x | -80.01x | -49.10x | -55.77x | -29.03x | -113.29x | -155.75x | - | - | -337.00x | -40.31x | -65.60x | -149.88x | - | 1282.50x | -6147.00x | -6433.75x | - | - | - | - |
| Total Equity | 5.43M | 2.22M | 4M | 5.33M | 6.25M | 6.98M | 8.32M | 3.62M | 2.69M | 4.89M | 4.68M | 6.79M | 9.42M | 3.44M | 2.83M | 7K | 1.43M | 8.56M | 22.76M | 11.25M | 19.6M | 20.61M |
| Equity Growth % | 144.82% | -44.49% | -25.01% | -14.66% | -10.47% | -16.13% | 129.95% | 34.69% | -45.02% | 4.45% | -31.04% | -28% | 173.64% | 21.52% | 40385.71% | -99.51% | -83.35% | -62.37% | 102.28% | -42.6% | -4.88% | - |
| Book Value per Share | 49.40 | 26.07 | 46.97 | 55.45 | 77.78 | 86.88 | 103.58 | 49.26 | 62.75 | 118.60 | 129.51 | 194.20 | 277.06 | 108.03 | 159.95 | 0.25 | 51.28 | 1199.44 | 3610.41 | 213.64 | 456.98 | 5903.18 |
| Total Shareholders' Equity | 5.43M | 2.22M | 4M | 5.33M | 3.61M | 6.98M | 8.32M | 3.62M | 2.69M | 4.89M | 4.66M | 6.26M | 7.35M | 3.44M | 2.83M | 7K | 1.43M | 8.56M | 22.76M | 11.25M | 19.6M | 20.61M |
| Common Stock | 23.14M | 14.12M | 14.12M | 14.12M | 13.18M | 13.18M | 13.18M | 13.18M | 6.62M | 6.61M | 6.2M | 6.09M | 6M | 5.33M | 4.99M | 1.45M | 1.45M | 1.44M | 1.07M | 864K | 841K | 594K |
| Retained Earnings | -159.01M | -158.25M | -156.47M | -155.13M | -155.6M | -153.93M | -152.59M | -155.65M | -154.9M | -152.49M | -148.32M | -146.07M | -143.56M | -143.28M | -142.14M | -141.22M | -149.11M | -139.86M | -114.92M | -99.79M | -85.78M | -69.3M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.5M | -2.09M | -2.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 20K | 20K | 20K | 20K | 20K | 20K | 20K | 67K | 183K | 20K | 9K | 9K | -90K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19K | 520K | 2.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and insolvency
As reported in recent financial filings, XTLB's total assets have declined from $4.9 million in 2022Q3 to $8.6 million in 2024Q4, while the company's accumulated deficit has ballooned to $159 million, signaling a persistent and accelerating deterioration of the firm's overall financial health and long-term viability.
The consistent expansion of the accumulated deficit suggests that the company has failed to achieve any meaningful commercial milestones to offset its operational burn. This trajectory indicates that the business model remains entirely dependent on external capital injections rather than internal value creation.
Based on the company's 2024Q4 balance sheet, cash reserves have plummeted to $371,000, resulting in a current ratio of 0.61, which suggests that the firm lacks the necessary liquidity to cover its short-term obligations without immediate and potentially highly dilutive capital market intervention.
The sharp decline in the current ratio from over 20.0 in previous periods highlights a rapid depletion of the company's safety buffer. Investors should monitor the firm's ability to secure funding, as the current cash position appears insufficient to sustain ongoing research and administrative overhead for the coming year.
According to recent SEC filings, XTLB's asset base is increasingly concentrated in goodwill, which rose to $3.2 million in 2024Q4, representing a significant portion of the company's total assets and raising concerns regarding potential future impairment charges if clinical trial progress remains stalled.
The reliance on intangible assets in the absence of commercialized products suggests that the balance sheet is highly sensitive to subjective valuation assumptions. Any further delays in the hCDR1 pipeline could necessitate a write-down, further eroding the company's already thin equity base.
As indicated by the provided data, the sudden appearance of $138,000 in debt in 2024Q4, following a long period of being debt-free, suggests that the company is resorting to emergency financing measures that may carry restrictive covenants or further dilute existing shareholders to maintain basic operations.
The shift toward debt financing, however small, warrants investigation into the terms of these obligations and whether they signal a loss of access to equity markets. This development may indicate that the company is reaching a point of financial desperation that could compromise future strategic flexibility.
Quick answers to the most common questions about buying XTLB stock.
As of 2024, XTL Biopharmaceuticals Ltd. (XTLB) had total assets of $8.6M including $1.3M in current assets.
XTL Biopharmaceuticals Ltd. (XTLB) carries total debt of $0.1M, offset by $1.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
XTL Biopharmaceuticals Ltd. (XTLB) has total shareholders' equity (book value) of $5.4M ($49.40 book value per share). Book value represents the net worth of the company belonging to common stock holders.
XTL Biopharmaceuticals Ltd. (XTLB) reported a current ratio of 0.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.